Alyeska Investment Group
PTGX icon

Alyeska Investment Group’s Protagonist Therapeutics PTGX Stock Holding History

Alyeska Investment Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109M Buy
889,298
+296,101
+50% +$30.9M 0.28% 85
2026
Q1 		$62.5M Buy
593,197
+393,674
+197% +$34.9M 0.18% 158
2025
Q4 		$17.4M Buy
+199,523
New +$16.3M 0.05% 331
2018
Q1 		– Sell
-50,000
Closed -$1.04M – 500
2017
Q4 		$1.04M Buy
+50,000
New +$887K 0.01% 380

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Alyeska Investment Group's PTGX Position: Q2 2026 in Review

Alyeska Investment Group increased its Protagonist Therapeutics (PTGX) stake by 50% in Q2 2026, buying an estimated $30.9M and bringing the position to 889,298 shares worth $109M. The position accounts for 0.28% of the portfolio, ranked #85.

Alyeska Investment Group first reported a position in PTGX in Q4 2017 and has held it in 4 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Alyeska Investment Group held 889,298 shares of Protagonist Therapeutics worth $109M as of Q2 2026.
  • Alyeska Investment Group bought 296,101 Protagonist Therapeutics shares in Q2 2026, an estimated $30.9M.
  • Protagonist Therapeutics made up 0.28% of Alyeska Investment Group's portfolio in Q2 2026, its #85 holding.
  • Alyeska Investment Group first reported a position in Protagonist Therapeutics in Q4 2017 and has held it in 4 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.